SEC Form 4 · accession 0001144204-19-013779
Edesa Biotech, Inc. · EDSA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Louis Hill
Director
Period of report
Mar 12, 2019
Accepted (ET)
Mar 13, 2019 · 7:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001540159
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $1.25 | Mar 12, 2019 | A | 357 | A | — | Mar 12, 2026 | Common Shares | 357 | 357 | D |
Explanation of responses
- F1Option grant under the 2017 Incentive Compensation Plan, which shall vest as to one-third immediately, as to one-third on March 12, 2020 and as to the remaining one-third on September 12, 2020.